AMENDMENTS TO THE SPECIFICATION UNDER 37 C.F.R. § 1.121(b)(1)

In the DETAILED DESCRIPTION section on page 4, after line 28 please insert the following two new paragraphs:

The present selenophene compounds are readily prepared using art-recognized chemical synthesis procedures as exemplified in Example 1 and in Examples 3-8. This invention is further envisioned from the chemical concept on the basis of a coherent design as shown in Scheme 3 in Example 2. This chemical concept provides the foundation for conceiving the preparation and utility of numerous "hybrid" selenophene compounds containing other related five-membered heterocycles, such as furan, thiophene and pyrrole, and their analogs. Moreover, the practice of this chemical concept is substantiated by Example 2 and by Examples 9-33. The anticancer utility of these hybrid selenophene compounds is manifested by (a) selective cytotoxicity for human renal carcinoma cells in comparison to normal human renal cells (Table 1), (b) antitumor cytotoxicity against a variety of human tumor cells (Example 53), (c) *in vivo* antitumor activity against human lung tumor (Example 54), and (d) inhibition of protein kinase C activity (Table 2).

In corroboration with the above chemical concept, a versatile, alternative synthetic design is further conceived for the preparation of relevant "hybrid" selenophene compounds as in the scheme shown in Example 34. The practice of this synthetic design is supported by Examples 34-50. The anticancer utility of these hydrid selenophene compounds is indicated by (a) selective cytotoxicity for human renal carcinoma cells in comparison to normal human renal cells (Table 1), (b) antitumor cytotoxicity against a variety of human tumor cells (Example 53), (c) *in vivo* antitumor activity against human lung tumor (Example 54) and (d) inhibition of protein kinase C (Table 2).

Please delete the title SELENOPHENE ANTI-TUMOR AGENTS on page 101 (the Abstract page).